What acute and preventive migraine therapies are appropriate for a patient whose rizatriptan (two doses 2 hours apart) failed and who has not received onabotulinumtoxinA (Botox) injections for 22 years?

Acute Migraine Management After Rizatriptan Failure

When rizatriptan fails even with two doses, immediately add an NSAID (such as naproxen 500-550 mg or ibuprofen 400-600 mg) to create combination therapy, as this significantly improves efficacy compared to triptan monotherapy. 1

Immediate Next Steps for This Acute Attack

First-Line Rescue Strategy

• Combine rizatriptan with an NSAID if the patient has been taking rizatriptan alone. The 2025 American College of Physicians guidelines emphasize that combination therapy (triptan + NSAID or acetaminophen) is superior to monotherapy and should be initiated early in the attack 1
• If NSAIDs are contraindicated, combine with acetaminophen instead 1

If Combination Therapy Still Fails

Switch to a different triptan before abandoning the class entirely. Evidence demonstrates that 25-81% of patients who fail one triptan will respond to another triptan 2. Consider:

• Sumatriptan (especially subcutaneous or nasal spray for faster onset)
• Eletriptan
• Zolmitriptan
• Almotriptan

The variation in response occurs due to differences in absorption, individual pharmacokinetics, and receptor binding profiles 1, 2.

Third-Line Options for Refractory Acute Attacks

If combination therapy with multiple triptans fails, consider CGRP antagonists (gepants) 1:

• Rimegepant 75 mg
• Ubrogepant 50-100 mg
• Zavegepant nasal spray

These are specifically recommended for patients with inadequate response to triptan + NSAID combination therapy 1.

Alternative: Dihydroergotamine (DHE)

• Consider DHE (intranasal or injectable) as another option for triptan failures 1
• Particularly useful if nausea/vomiting is prominent (combine with antiemetic) 1

Last Resort for Acute Treatment

Lasmiditan is reserved for patients who fail all other treatments in the guideline 1

Critical Pitfalls to Avoid

⚠️ Do NOT use opioids or butalbital - these are explicitly contraindicated for migraine treatment 1

⚠️ Medication Overuse Headache Risk: Using triptans ≥10 days per month can cause medication overuse headache 1. If this patient is using rizatriptan frequently, this may be contributing to treatment failure.

Preventive Therapy Considerations

This patient needs preventive therapy restarted immediately given:

1. Frequent attacks requiring multiple acute medication doses
2. History of Botox use (indicating chronic/frequent migraine)
3. 22-year gap without prevention suggests undertreated disease 3

Preventive Options to Discuss:

First-line preventive agents 3:

• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) - particularly effective in patients with prior treatment failures 4
• Restart onabotulinumtoxinA (Botox) if chronic migraine (≥15 headache days/month) - the patient previously responded to this 5, 6
• Traditional preventives: propranolol, topiramate, or amitriptyline

Recent evidence shows CGRP-targeted therapies are particularly effective in patients with prior preventive treatment failures, with low-to-moderate certainty evidence supporting their use 4.

Sequential Strategy

If restarting Botox, recent real-world data shows 74% of chronic migraine patients don't achieve ≥50% response after 3 Botox cycles, at which point transition to anti-CGRP mAbs is appropriate 6. Consider starting with CGRP mAbs directly given the long gap in treatment.

Practical Algorithm

1. Today's attack: Add NSAID to rizatriptan (if not already doing so)
2. Next attack: Try different triptan + NSAID combination
3. If still failing: Switch to gepant (rimegepant/ubrogepant)
4. Simultaneously: Initiate preventive therapy (CGRP mAb or restart Botox)
5. Monitor: Ensure not exceeding 10 days/month of acute medication use

The combination of optimized acute treatment with appropriate prevention addresses both immediate symptom relief and long-term disease modification, which is essential for improving quality of life and reducing migraine-related disability 1, 3.